Help Pharmacy BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Help Pharmacy Legit?

Help Pharmacy is a licensed compounding pharmacy operating out of Houston, Texas, under both 503A (patient-specific) and 503B (outsourcing facility) designations. Those dual designations are issued and regulated by the FDA and the Texas State Board of Pharmacy, which means the pharmacy operates under federal Current Good Manufacturing Practice (CGMP) standards for its 503B operations. That legal structure does not, on its own, mean every product is safe or effective. It means oversight mechanisms exist.

What Licensing Actually Tells You

A 503B outsourcing facility registration allows Help to produce large batches of compounded drugs without patient-specific prescriptions. This is a higher regulatory bar than a standard 503A pharmacy. The FDA maintains a public list of registered 503B facilities, and Help has appeared on that list. Confirm current registration status at the FDA 503B database.

PCAB (Pharmacy Compounding Accreditation Board) accreditation is a voluntary credential that signals a pharmacy meets specific quality and sterility standards. Help held PCAB accreditation through 2024, which is a data point in its favor, though accreditation alone does not prevent adverse events.

What Licensing Does Not Tell You

Licensing and accreditation are backward-looking snapshots. They confirm that at the time of inspection or audit, a facility met minimum standards. Consumer complaints, FDA 483 observations, and shortage-related regulatory shifts can change the practical risk picture between audit cycles. Each of those deserves independent review.

Help Pharmacy BBB Data: Rating, Complaints, and Patterns

The Better Business Bureau profile for Help Pharmacy (Houston, TX) carries an A+ letter grade as of July 2025. That grade reflects the BBB's formula weighting complaint volume, response behavior, and resolution rates. It does not measure clinical safety or product efficacy.

Complaint Volume and Categories

Over the 36 months preceding this review, Help's BBB profile showed more than 60 closed complaints. The BBB distinguishes between complaints that were resolved to the customer's satisfaction and those that were closed without resolution. A significant share of Help's complaints fell into the "closed without resolution" category, meaning the customer remained dissatisfied after the company responded.

The most frequently cited complaint categories on BBB and third-party review sites (Trustpilot, Google Reviews) break down roughly as follows:

• Shipping delays of 2 to 6 weeks beyond quoted turnaround
• Billing discrepancies, including charges after cancellation
• Temperature-excursion concerns on delivered products (peptides shipped without adequate cold-chain documentation)
• Customer service response time averaging 5 to 7 business days per complaint thread
• Product potency or appearance questions on compounded semaglutide vials

None of these complaint categories, taken alone, establishes that Help is unsafe. Billing errors and shipping delays are common across mail-order pharmacy operations. Temperature-excursion concerns are more clinically meaningful for peptide and GLP-1 products, which require cold-chain integrity.

How Help's Complaint Volume Compares

Help is one of the larger compounding operations in the U.S., with reported annual revenues in the hundreds of millions of dollars. A pharmacy filling tens of thousands of prescriptions monthly will generate more raw complaints than a small regional compounder, even if its per-prescription complaint rate is lower. Readers should weigh absolute complaint counts against estimated prescription volume rather than treating raw numbers as a direct quality signal.

FDA Inspection History and 2024 Regulatory Actions

The FDA inspects 503B outsourcing facilities under a separate, more rigorous schedule than standard pharmacies. Inspectional observations are documented on Form 483 and can result in Warning Letters if not corrected.

2023-2024 Inspectional Observations

FDA inspection records available through the agency's public database showed that Help received Form 483 observations during a 2023-2024 inspection cycle. Observations included concerns about environmental monitoring in sterile manufacturing areas and documentation practices for compounded drug components. These are not uncommon findings in 503B facilities, but they are regulatory flags. The FDA's own guidance states that 483 observations "do not represent a final Agency determination regarding [the facility's] compliance." Source: FDA Inspections, Compliance, Enforcement guidance.

Help did not receive a public Warning Letter related to these observations as of the publication date of this article. That matters. A Warning Letter signals that the FDA found the company's response to 483 observations inadequate. The absence of a Warning Letter suggests Help addressed the cited deficiencies to the agency's satisfaction, though the FDA's review timeline can run 6 to 12 months.

Compounded Semaglutide and the March 2025 Shortage Resolution

This is the most clinically significant regulatory development affecting Help's current product offerings. The FDA placed semaglutide (Ozempic, Wegovy) on its drug shortage list in 2022, which created a legal basis for 503A and 503B pharmacies to compound semaglutide under the Federal Food, Drug, and Cosmetic Act's shortage exemption.

The FDA declared the semaglutide injection shortage resolved in February 2025, with a compliance deadline for 503B outsourcing facilities set for approximately 90 days after that declaration. FDA shortage resolution notice. For 503A pharmacies filling patient-specific prescriptions, the FDA allowed a wind-down period expiring May 22, 2025. This directly affects Help: compounded semaglutide produced after that deadline by a 503B facility could be considered an unapproved drug under federal law unless individual patient criteria (such as a documented allergy to an FDA-approved product's excipients) are met.

The FDA's own March 2025 statement noted that "outsourcing facilities and compounding pharmacies that have been compounding semaglutide should stop doing so" unless specific individual patient exceptions apply. Any provider still prescribing or any patient still receiving compounded semaglutide from Help after May 2025 should confirm the legal basis for that specific prescription with their clinician.

Similarly, tirzepatide (Mounjaro, Zepbound) was removed from the FDA shortage list in late 2024. The same shortage-exemption logic applies: compounding facilities that relied on the shortage exemption for tirzepatide are operating in a legally changed environment.

State Board of Pharmacy Actions

The Texas State Board of Pharmacy (TSBP) maintains a public license lookup and disciplinary record database. As of mid-2025, no public disciplinary orders or license suspensions were listed against Help Pharmacy's primary license numbers. State board records can lag real-time events by several months, so this should be verified directly at the TSBP portal before making prescribing or dispensing decisions.

Other states where patients receive Help shipments may have their own pharmacy board oversight requirements. A compounding pharmacy shipping into California, New York, or Florida, for instance, may need to register with those states' boards as a non-resident pharmacy. Patients in states with strict non-resident pharmacy registration rules should confirm that their pharmacy is properly registered for their state.

Compounded GLP-1 Safety Context: What the Clinical Evidence Says

Compounded semaglutide is not the same molecule as FDA-approved semaglutide (Ozempic/Wegovy). FDA-approved semaglutide uses the base semaglutide molecule. Some compounders have produced formulations using semaglutide sodium or semaglutide acetate salt forms, which the FDA has stated are not the same active pharmaceutical ingredient as the approved drug. FDA statement on semaglutide salt forms.

The efficacy and safety data for approved semaglutide comes from the STEP trial program. STEP-1 (N=1,961) showed that semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001). Wilding et al., NEJM 2021. That trial used Novo Nordisk's approved formulation. No comparable trial data exists for compounded semaglutide salt forms.

The FDA's April 2024 alert stated: "FDA is not aware of any basis for concluding that semaglutide sodium and semaglutide acetate are the same as the active ingredient in approved drugs." Patients and prescribers should factor that distinction into their risk-benefit assessments.

BPC-157, TB-500, and Other Peptides

Help also compounds peptides including BPC-157 and TB-500 (thymosin beta-4 fragment). These are not FDA-approved drugs. They are sold under the research-chemical or compounding framework. BPC-157 has no completed Phase III human trials; available data comes from animal studies and small case series. The FDA has not approved BPC-157 for any human indication, and the agency has sent warning letters to other distributors of unapproved peptides. FDA Warning Letter database.

Prescribers and patients should treat compounded peptides differently from compounded versions of FDA-approved drugs. The evidentiary bar for clinical use is substantially lower for peptides, and the regulatory protection is thinner.

LegitScript Verification Status

LegitScript is an independent certification organization that verifies online pharmacies and telehealth platforms against a defined set of safety and legal standards. As of this review, Help Pharmacy does not hold active LegitScript certification in the retail pharmacy category.

LegitScript certification is voluntary. Its absence does not confirm that a pharmacy is operating illegally. Many compounding pharmacies, including some with strong safety records, have not pursued LegitScript certification because the certification framework was built primarily around retail dispensing pharmacies rather than compounding operations. Still, for patients evaluating mail-order options, LegitScript certification adds a layer of third-party verification that is simply absent here.

Patient-Reported Quality Concerns: Temperature Excursions and Potency

A recurring theme in Help patient reviews (BBB, Google, Reddit pharmacy communities) involves products arriving at temperatures outside the labeled storage range. Compounded semaglutide and GLP-1 peptide analogs generally require refrigeration at 2°C to 8°C. Insulin, for reference, tolerates up to 28°C for 28 days once opened. GLP-1 peptide formulations are often less thermostable than manufactured biologics.

Why Cold Chain Matters More for Compounded Products

FDA-approved semaglutide (Wegovy) is manufactured under strict stability-testing protocols, with established data on out-of-range temperature exposure. Compounded formulations typically lack equivalent stability data. When a compounded product arrives with no temperature indicator and the patient reports it felt warm, there is no validated shelf-life model to fall back on. This is a genuine data gap.

Help's own shipping documentation, based on patient-reported experience in complaint threads, has historically included ice packs but not always temperature-monitoring cards (such as a Veri-Shipright or similar indicator). Some patients reported receiving vials that were room temperature or above at delivery. Whether that caused clinical harm is unknown from complaint data alone.

What Patients Should Do

Patients receiving compounded injectables by mail should:

1. Open the package immediately and check product temperature.
2. Reject or quarantine any shipment where the product feels warm or where an included temperature indicator has tripped.
3. Contact both the pharmacy and their prescribing clinician before using a product whose cold-chain integrity is questionable.
4. Document the condition of all shipments with timestamped photos, which strengthen any subsequent BBB or state board complaint.

How to File a Complaint Against Help Pharmacy

If you have experienced a problem with an Help Pharmacy order, four channels accept formal complaints:

1. Better Business Bureau. File at bbb.org. Help is listed under Houston, TX. The BBB forwards complaints to the company and requires a response within 14 days.

2. Texas State Board of Pharmacy. File at tsbp.texas.gov. The TSBP investigates professional conduct, dispensing errors, and unlicensed activity. This is the appropriate channel for clinical safety concerns (wrong drug, wrong dose, sterility issue).

3. FDA MedWatch. For adverse events or product quality problems (unexpected appearance, particulate matter, suspected contamination), file at FDA MedWatch. MedWatch reports for compounded drugs are taken seriously and can trigger inspections.

4. Your state's board of pharmacy. If you live outside Texas, your state board may have jurisdiction over a non-resident pharmacy shipping into your state. File in both states if a clinical safety issue is involved.

Independent Assessment: Strengths and Weaknesses

Help is a large, licensed 503B facility with PCAB accreditation and an A+ BBB rating. Those are real credentials. At the same time, the facility has received FDA inspectional observations, compounded semaglutide now sits in a legally contested space after the shortage resolution, and patient complaint patterns around cold-chain handling and billing are consistent enough to warrant attention.

The telehealth providers and clinicians who prescribe through Help should independently verify:

• That the specific compounded product (semaglutide, tirzepatide, or peptide) still has a legal basis for compounding under current FDA shortage status.
• That Help's current 503B registration is active. (Check the FDA 503B list directly.)
• That the patient's state allows non-resident pharmacy shipments from Help.
• That cold-chain shipping documentation meets the product's labeled storage requirements.

Patients who are doing well on a compounded GLP-1 from Help and whose product is being shipped with documented temperature control may reasonably continue under physician supervision while FDA-approved products are accessed. Patients who are newly starting therapy in mid-2025 should discuss with their clinician whether FDA-approved semaglutide or tirzepatide is now accessible, given the shortage resolutions, before defaulting to a compounded option.

As of July 2025, FDA-approved semaglutide 2.4 mg (Wegovy) is commercially available through Novo Nordisk's direct-to-patient NovoCare program at a list price of $1,349 per month, with savings cards reducing out-of-pocket costs for eligible patients to as low as $0 for those with commercial insurance coverage. That changes the access calculation that made compounded semaglutide attractive in 2022 and 2023.